Development of liposomal anticancer drugs

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 5, 2013, Pages 703-707

  Hyodo, Kenji ^a   Yamamoto, Eiichi ^a   Suzuki, Takuya ^a   Kikuchi, Hiroshi ^a   Asano, Makoto ^a   Ishihara, Hiroshi ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Accelerated blood clearance phenomenon; Anticancer drug; Drug delivery system; Enhanced permeability and retention effect; Liposome; Therapeutic efficacy

Indexed keywords

DOXORUBICIN; LIPOSOME; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG STRUCTURE; ENCAPSULATION; HEAD AND NECK CANCER; MELANOMA; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; REVIEW; SOLID PHASE EXTRACTION; ULTRACENTRIFUGATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPOSOMES; NEOPLASMS; QUALITY CONTROL;

EID: 84876914209     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01106     Document Type: Review

References (33)

1. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine, 7, 49-60 (2012).
2. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer, 6, 688-701 (2006).
3. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim. Biophys. Acta, 1113, 171-199 (1992).
4. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A., 85, 6949-6953 (1988).
5. Gabizon A, Martin F. Polyethylene glycol-coated (PEGylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs, 54 (Suppl 4), 15-21 (1997).
6. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 65, 271-284 (2000).
7. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 41, 189-207 (2001).
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392 (1986).
9. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst., 99, 1441-1454 (2007).
10. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta, 1151, 201-215 (1993).
11. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta, 1331, 187-211 (1997).
12. Beijnen JH, van der Houwen OAGJ, Underberg WJM. Aspects of the degradation kinetics of doxorubicin in aqueous solution. Int. J. Pharm., 32, 123-131 (1986).
13. Johnston MJ, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D, Cullis PR. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim. Biophys. Acta, 1758, 55-64 (2006).
14. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res., 49, 5922-5930 (1989).
15. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta, 1663, 167-177 (2004).
16. Peyrl A, Sauermann R, Traunmueller F, Azizi AA, Gruber-Olipitz M, Gupper A, Slavc I. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Clin. Pharmacokinet., 48, 265-271 (2009).
17. Druckmann S, Gabizon A, Barenholz Y. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochim. Biophys. Acta, 980, 381-384 (1989).
18. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal. Biochem., 188, 65-71 (1990).
19. Ahmad A, Wang YF, Ahmad I. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice. Methods Enzymol., 391, 176-185 (2005).
20. Deshpande NM, Gangrade MG, Kekare MB, Vaidya VV. Determination of free and liposomal amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 878, 315-326 (2010).
21. Mayer LD, St-Onge G. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal. Biochem., 232, 149-157 (1995).
22. Jiang W, Lionberger R, Yu LX. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis, 3, 333-344 (2011).
23. Yamamoto E, Hyodo K, Ohnishi N, Suzuki T, Ishihara H, Kikuchi H, Asakawa N. Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE-SPE-HPLC. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 879, 3620-3625 (2011).
24. Yamamoto E, Murata K, Ishihama Y, Asakawa N. Methylcellulose-immobilized reversed-phase precolumn for direct analysis of drugs in plasma by HPLC. Anal. Sci., 17, 1155-1159 (2001).
25. Desilets CP, Rounds MA, Regnier FE. Semipermeable-surface reversed-phase media for high-performance liquid chromatography. J. Chromatogr. A, 544, 25-39 (1991).
26. Cassiano NM, Lima VV, Oliveira RV, de Pietro AC, Cass QB. Development of restricted-access media supports and their application to the direct analysis of biological fluid samples via high-performance liquid chromatography. Anal. Bioanal. Chem., 384, 1462-1469 (2006).
27. Cassiano NM, Barreiro JC, Moraes MC, Oliveira RV, Cass QB. Restricted-access media supports for direct high-throughput analysis of biological fluid samples: review of recent applications. Bioanalysis, 1, 577-594 (2009).
28. Yamamoto E, Kato T, Mano N, Asakawa N. Effective on-line extraction of drugs from plasma using a restricted-access media column in column-switching HPLC equipped with a dilution system: application to the simultaneous determination of ER-118585 and its metabolites in canine plasma. J. Pharm. Biomed. Anal., 49, 1250-1255 (2009).
29. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 292, 1071-1079 (2000).
30. Ishida T, Ichihara M, Wang XY, Yamamoto K, Kimura J, Majima E, Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release, 112, 15-25 (2006).
31. Ishida T, Wang XY, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release, 122, 349-355 (2007).
32. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther., 298, 607-612 (2001).
33. Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T, Kiwada H, Ishihara H, Kikuchi H. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int. J. Pharm., 436, 636-643 (2012).